Last reviewed · How we verify
BZ371A
At a glance
| Generic name | BZ371A |
|---|---|
| Sponsor | Biozeus Biopharmaceutical S.A. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of the Efficacy in Increasing Sexual Arousal, Safety and Tolerability of BZ371A in Women With Sexual Arousal Disorder (PHASE2)
- Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered (PHASE1)
- Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients (PHASE2)
- Evaluation of the Efficacy, Safety and Tolerability of BZ371A in Women with Sexual Arousal Disorder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BZ371A CI brief — competitive landscape report
- BZ371A updates RSS · CI watch RSS
- Biozeus Biopharmaceutical S.A. portfolio CI